Literature DB >> 9086129

Is there a general tendency for CD4 lymphocyte decline to speed up during human immunodeficiency virus infection? Evidence from the Italian Seroconversion Study.

A C Lepri1, C A Sabin, P Pezzotti, P D England, A N Phillips, G Rezza.   

Abstract

It has been suggested that the rate of CD4 cell decline accelerates in parallel with decreasing numbers of cells; however, the statistical literature suggests the opposite. CD4 cells were counted about every 6 months in a cohort of 1264 human immunodeficiency virus-infected subjects (the Italian Seroconversion Study cohort). Kaplan-Meier analysis was used to estimate the time for CD4 cells to decline by 100 cells/mm3, conditional on reaching predefined levels. In addition, CD4 cell counts were modeled as a function of time since seroconversion in individuals with > or = 5 counts. Kaplan-Meier survival times for a 100 cell/mm3 decrease in CD4 cells increased as lower counts were reached (log rank test, P < .001). The shape of the overall fitted curve of the CD4 cell counts does not suggest an increasing rate of decline. Data from the Italian Seroconversion Study cohort do not show a general tendency for accelerating CD4 cell decline in association with lower counts.

Entities:  

Mesh:

Year:  1997        PMID: 9086129     DOI: 10.1086/513970

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  8 in total

Review 1.  The role of antigenic stimulation and cytotoxic T cell activity in regulating the long-term immunopathogenesis of HIV: mechanisms and clinical implications.

Authors:  C Fraser; N M Ferguson; F de Wolf; R M Anderson
Journal:  Proc Biol Sci       Date:  2001-10-22       Impact factor: 5.349

2.  Development and validation of decision rules to guide frequency of monitoring CD4 cell count in HIV-1 infection before starting antiretroviral therapy.

Authors:  Thierry Buclin; Amalio Telenti; Rafael Perera; Chantal Csajka; Hansjakob Furrer; Jeffrey K Aronson; Paul P Glasziou
Journal:  PLoS One       Date:  2011-04-08       Impact factor: 3.240

3.  Estimating the resources required in the roll-out of universal access to antiretroviral treatment in Zimbabwe.

Authors:  T B Hallett; S Gregson; S Dube; E S Mapfeka; O Mugurungi; G P Garnett
Journal:  Sex Transm Infect       Date:  2011-06-02       Impact factor: 3.519

4.  Clinical prognostic value of RNA viral load and CD4 cell counts during untreated HIV-1 infection--a quantitative review.

Authors:  Eline L Korenromp; Brian G Williams; George P Schmid; Christopher Dye
Journal:  PLoS One       Date:  2009-06-17       Impact factor: 3.240

5.  The impact of monitoring HIV patients prior to treatment in resource-poor settings: insights from mathematical modelling.

Authors:  Timothy B Hallett; Simon Gregson; Sabada Dube; Geoff P Garnett
Journal:  PLoS Med       Date:  2008-03-11       Impact factor: 11.069

6.  Late entry to HIV care limits the impact of anti-retroviral therapy in The Netherlands.

Authors:  Colette Smit; Timothy B Hallett; Joep Lange; Geoff Garnett; Frank de Wolf
Journal:  PLoS One       Date:  2008-04-09       Impact factor: 3.240

7.  The impact of antiretroviral therapy on population-level virulence evolution of HIV-1.

Authors:  Hannah E Roberts; Philip J R Goulder; Angela R McLean
Journal:  J R Soc Interface       Date:  2015-12-06       Impact factor: 4.118

Review 8.  Comparative Analysis of Tat-Dependent and Tat-Deficient Natural Lentiviruses.

Authors:  Deepanwita Bose; Jean Gagnon; Yahia Chebloune
Journal:  Vet Sci       Date:  2015-09-29
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.